Comparative evaluation of dentinal hypersensitivity by a nano-hydroxyapatite and herbal formulated desensitizing toothpaste in patients with dentinal hypersensitivity: A randomized controlled trial

Phase 2

Conditions: Health Condition 1: K038- Other specified diseases of hard tissues of teeth

Registration Number: CTRI/2023/05/052295

Lead Sponsor: Dr Sumedha Meenal Thosar

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1) Patients with dentine hypersensitivity in single or multirooted teeth on consumption of cold food stuff, air blast and on slightly moving the probe over the defect surface.

2) Patient with age group of 25-50 years.

3) Patients with sensitivity score > 2 on the visual analogue scale (VAS)

4) Patient having good general and periodontal health (no probing depth exceeding 4 mm and no bleeding on probing);

5)Those patients that have recession of gingiva

6)Teeth with erosion and abrasion.

7)Patient willing to give consent for the study.

Exclusion Criteria

1) Teeth with dental caries or extensive restoration (involving more than 50% of the tooth structure), which might have an abnormal pulpal response;

2) Destructive periodontal diseases;

3) Patients with chronic systemic diseases associated with intermittent episodes of constant daily pain.

4) Tooth mobility > grade I.

5) Patients undergone vital tooth bleaching or orthodontic appliance treatment within previous three months.

6) Patients who had used desensitising agents in past six months.

7) Patients with pregnancy or in lactating period.

8) Patients who smoke or do alcohol abuse.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate difference in relief of dentinal hypersensitivity using a nano-hydroxyapatite and herbal desensitizing tooth paste as compared to control group over a period of 8 weeks in patients with dentinal hypersensitivity.Timepoint: baseline, 1 week, 4 weeks, 8 weeks from baseline

Secondary Outcome Measures